ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the structure of erythropoietin (EPO). Unlike EPO itself, ARA-290 was specifically designed to activate the tissue-protective receptor — the EPO receptor/CD131 (β-common receptor) heterodimer — without stimulating red blood cell production through the classical homodimeric EPO receptor. This separation of tissue-protective from haematopoietic effects was the central design objective.[1][2]

ARA-290 has progressed further through clinical development than most research peptides, with completed phase 2 trials in diabetic neuropathy and diabetic macular oedema. The peptide represents a targeted approach to harnessing EPO’s cytoprotective signalling without the dangerous side effects (thrombosis, hypertension) associated with EPO’s erythropoietic activity.[3]

Compound Profile

What Does ARA-290 Actually Do?

ARA-290 research demonstrates tissue-protective and anti-inflammatory effects across multiple organ systems without affecting red blood cell production. The peptide activates the innate repair receptor (IRR) — the EPO receptor/CD131 heterodimer — triggering cytoprotective signalling cascades that reduce apoptosis, inflammation, and tissue damage.[1][2]

In clinical studies, ARA-290 has shown effects on small nerve fibre regeneration in type 2 diabetes patients with neuropathy, improvement in corneal nerve fibre density, and reduction of neuropathic pain scores. A phase 2 trial in diabetic macular oedema demonstrated anti-inflammatory effects on retinal pathology.[3][4]

How ARA-290 Works

ARA-290’s mechanism centres on selective activation of the innate repair receptor (IRR), a heterodimeric receptor complex composed of the EPO receptor and CD131 (β-common receptor). This receptor is expressed on neurons, endothelial cells, cardiomyocytes, and immune cells, but is distinct from the homodimeric EPO receptor that drives erythropoiesis.[1][2]

Anti-apoptotic signalling: IRR activation triggers JAK2/STAT5 and PI3K/Akt survival pathways, promoting cell survival under stress conditions including ischaemia, inflammation, and metabolic injury. ARA-290 has been shown to protect against cisplatin-induced nephrotoxicity through these pathways.[5]

Anti-inflammatory modulation: ARA-290 modulates innate immune responses, reducing pro-inflammatory cytokine production and shifting macrophage polarisation toward reparative phenotypes. This immune modulation has been demonstrated in models of autoimmune uveitis and haemolytic-uraemic syndrome.[6][7]

Neuroprotective effects: In cerebral ischaemia models, ARA-290 mediated brain tissue protection through β-common receptor-dependent pathways, reducing infarct volume and improving neurological outcomes.[8]

Recovery & Sleep Context

ARA-290’s tissue-protective profile is directly relevant to recovery research. The peptide’s ability to protect tissues from ischaemic, inflammatory, and metabolic insults — while promoting reparative immune responses — represents a recovery-supportive mechanism at the cellular level.[1][2]

Clinical evidence in diabetic neuropathy patients showed ARA-290 promoted small nerve fibre regeneration, suggesting active tissue repair rather than merely damage prevention. This regenerative capacity distinguishes ARA-290 from purely protective agents and places it in the tissue recovery domain.[3]

Preclinical cardiac research demonstrated ARA-290 reduced cardiac inflammation and attenuated age-associated declines in heart function, suggesting recovery-relevant effects in cardiovascular tissue.[9] Direct evidence linking ARA-290 to sleep or systemic recovery metrics is absent. Compare with BPC-157 and TB-500 for related tissue repair profiles, or see the Recovery & Sleep goal page.

Injury & Tissue Support Context

The injury and tissue support context is arguably ARA-290’s strongest research domain. The peptide was designed specifically to harness EPO’s tissue-protective signalling — a pathway evolved to protect tissues from injury-related damage.[1]

Preclinical models have demonstrated ARA-290’s protective effects across diverse injury types: cerebral ischaemia, cisplatin nephrotoxicity, haemolytic-uraemic syndrome, autoimmune uveitis, and diabetic neuropathy. The breadth of tissue responsiveness reflects the wide expression pattern of the EPO/CD131 heteroreceptor across organ systems.[5][6][7][8]

Traumatic brain injury research has identified erythropoietin derivatives including ARA-290 as candidates for phase-targeted neuroprotection, where tissue-protective effects without haematopoietic stimulation address a key safety concern in TBI management.[10] See the Injury & Tissue Support goal page for broader context.

ARA-290 Benefits

• Selective tissue protection: Activates the protective EPO/CD131 receptor without stimulating erythropoiesis, avoiding thrombotic and hypertensive risks associated with EPO.[1][2]
• Clinical trial evidence: Phase 2 trials in diabetic neuropathy and macular oedema provide human efficacy and safety data — more clinical evidence than most research peptides.[3][4]
• Nerve fibre regeneration: Clinical evidence demonstrating small nerve fibre regrowth in diabetic neuropathy patients suggests genuine regenerative capacity.[3]
• Anti-inflammatory immune modulation: Shifts immune responses toward reparative phenotypes, addressing the inflammatory component of tissue injury.[6][7]
• Multi-organ protection: Preclinical evidence spans neural, cardiac, renal, retinal, and skeletal tissue — reflecting broad IRR expression.[5][8][9]

ARA-290 Side Effects

ARA-290 has a more established safety profile than most research peptides, thanks to phase 2 clinical trial data:

• No haematopoietic effects: Clinical studies confirmed ARA-290 does not affect haemoglobin, haematocrit, or red blood cell counts — validating the selective receptor targeting design.[3]
• Injection site reactions: Mild, transient injection site reactions were the most commonly reported adverse events in clinical trials.
• Generally well-tolerated: Phase 2 trials reported adverse event rates comparable to placebo, with no serious adverse events attributed to ARA-290.
• Limited long-term data: Clinical trial durations were relatively short (weeks to months). Long-term safety of sustained IRR activation remains uncharacterised.

Half-Life

ARA-290 has a plasma half-life of approximately 2–3 minutes after intravenous administration, reflecting rapid renal clearance of this small peptide. Despite the short circulating half-life, subcutaneous administration (used in clinical trials) produces a longer effective exposure through depot absorption, and downstream biological effects persist beyond peptide clearance through sustained intracellular signalling cascades.

Clinical dosing protocols have used daily subcutaneous injection, consistent with a pharmacodynamic duration of action exceeding the pharmacokinetic half-life.

Limits of Current Evidence

• No phase 3 trials completed: While phase 2 data is promising, ARA-290 has not completed the large-scale trials required for regulatory approval in any jurisdiction.
• Limited indication scope: Clinical data exists primarily for diabetic neuropathy and diabetic macular oedema. Extrapolation to other conditions relies on preclinical models.
• Commercial development uncertainty: The clinical development pathway for ARA-290 has been prolonged, raising questions about commercial viability and ongoing investment.
• Dose optimisation incomplete: Optimal dosing regimens for different indications have not been fully established.
• Receptor selectivity assumptions: While designed for IRR selectivity, complete absence of effects through other receptors has not been exhaustively demonstrated.

Verdict

ARA-290 represents one of the more pharmacologically sophisticated peptides in the research pipeline — a rationally designed molecule targeting a specific receptor heterodimer to separate tissue protection from erythropoiesis. The scientific premise is elegant, the preclinical data is extensive, and the phase 2 clinical results provide genuine human evidence for nerve fibre regeneration and tissue-protective effects.

The challenge is translational momentum. Despite promising early clinical data, ARA-290 has not progressed to phase 3 trials, and the commercial development pathway remains unclear. For researchers interested in EPO-derived cytoprotection, ARA-290 provides a well-characterised tool with unusually strong clinical validation for a research peptide — but its ultimate therapeutic role depends on continued clinical development.

FAQ

What is ARA-290?

ARA-290 (also known as cibinetide) is an 11-amino acid synthetic peptide derived from the structure of erythropoietin. It selectively activates the tissue-protective EPO receptor/CD131 heterodimer without stimulating red blood cell production, providing cytoprotective and anti-inflammatory effects.

What is cibinetide used for?

Cibinetide (ARA-290) has been investigated in phase 2 clinical trials for diabetic neuropathy and diabetic macular oedema. Preclinical research has explored its potential in cerebral ischaemia, cardiac injury, kidney protection, and autoimmune conditions. It is not currently approved for any clinical indication.

How does ARA-290 differ from EPO?

EPO activates the homodimeric EPO receptor, stimulating red blood cell production along with tissue protection. ARA-290 selectively activates only the EPO/CD131 heterodimer (innate repair receptor), providing tissue protection without erythropoietic stimulation. This avoids EPO’s risks of thrombosis and hypertension.

Has ARA-290 been tested in humans?

Yes. ARA-290 has completed phase 2 clinical trials in diabetic neuropathy (showing small nerve fibre regeneration) and diabetic macular oedema (showing anti-inflammatory retinal effects). It has not yet progressed to phase 3 trials.

What are ARA-290 side effects?

In phase 2 clinical trials, ARA-290 was generally well-tolerated with adverse event rates comparable to placebo. Mild injection site reactions were the most commonly reported side effect. Importantly, ARA-290 did not affect blood cell counts, confirming its selectivity for tissue-protective rather than haematopoietic pathways.

Is ARA-290 the same as EPO?

No. ARA-290 is a short 11-amino acid peptide derived from a specific region (helix B surface) of the much larger EPO molecule. It targets a different receptor complex and does not stimulate red blood cell production. ARA-290 was designed to capture EPO’s tissue-protective benefits without its haematopoietic effects.

References

1. Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med. 2012. PMID: 22354215
2. Liu G, et al. The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury. Int Immunopharmacol. 2024. PMID: 38943972
3. Rendell MS. The time to develop treatments for diabetic neuropathy. Expert Opin Investig Drugs. 2021. PMID: 33423557
4. Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med. 2020. PMID: 32674280
5. Ghassemi-Barghi N, et al. Mechanistic Approach for Protective Effect of ARA290 against Cisplatin-Induced Nephrotoxicity. Inflammation. 2023. PMID: 36085231
6. Merzbach S, et al. Anti-Inflammatory Effects of Clarstatin on Experimental Autoimmune Uveitis in Mice. Invest Ophthalmol Vis Sci. 2025. PMID: 39775697
7. Dennhardt S, et al. Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome. Front Immunol. 2022. PMID: 36211426
8. Wang RL, et al. Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemia. CNS Neurosci Ther. 2024. PMID: 38488446
9. Winicki NM, et al. A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function. Front Cardiovasc Med. 2022. PMID: 36741836
10. Sun Y, et al. Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy. Front Neurol. 2025. PMID: 41659975

PEG-MGF (PEGylated Mechano Growth Factor) is a modified form of the MGF splice variant of insulin-like growth factor 1 (IGF-1). MGF — also known as IGF-1Ec in humans — is produced naturally when muscle tissue is subjected to mechanical stress or damage, acting as a local repair signal distinct from systemic IGF-1.[1]

The PEGylated version attaches a polyethylene glycol (PEG) chain to the native MGF peptide, extending its biological half-life from minutes to hours. This modification was developed to address a key limitation of native MGF research: its extremely rapid degradation in biological fluids, which made studying its effects in vivo technically challenging.[2]

Compound Profile

What Does PEG-MGF Actually Do?

The mechano growth factor peptide functions as a local tissue repair signal. When muscle fibres experience mechanical loading or damage, the IGF-1 gene undergoes alternative splicing to produce MGF rather than systemic IGF-1. This local MGF expression activates satellite cells — the resident stem cells of skeletal muscle — prompting their proliferation and subsequent fusion with damaged muscle fibres.[1][3]

Research suggests MGF acts primarily in the initial phase of muscle repair, activating quiescent satellite cells before systemic IGF-1 takes over to drive differentiation and maturation. The PEG-MGF form allows researchers to study these effects with extended exposure windows that native MGF’s short half-life does not permit.[2]

How PEG-MGF Works

MGF’s mechanism centres on satellite cell activation through pathways distinct from those used by mature IGF-1. While both derive from the same gene, MGF’s unique Ec domain peptide sequence enables it to activate satellite cell proliferation without simultaneously driving differentiation — a distinction that has important implications for tissue repair sequencing.[1]

At the molecular level, MGF has been shown to signal through pathways including ERK1/2 MAPK and the Fyn-RhoA-YAP axis. Recent research demonstrated that MGF regulates periodontal ligament stem cell proliferation and differentiation through this Fyn-RhoA-YAP signalling cascade, suggesting its repair-promoting effects may extend beyond skeletal muscle.[4]

The PEGylation modification does not alter MGF’s receptor binding or signalling mechanisms. Instead, the PEG chain sterically shields the peptide from enzymatic degradation, extending its functional half-life without changing its biological activity profile.

Muscle Growth Context

PEG-MGF research is most directly relevant to muscle growth contexts, given MGF’s physiological role as the mechanically activated splice variant of IGF-1. The peptide’s primary function — satellite cell activation following mechanical stress — is the initial step in the muscle repair and hypertrophy cascade.[1]

In vitro studies have demonstrated that MGF increases myoblast proliferation rates and delays differentiation, expanding the pool of satellite cells available for muscle repair. This contrasts with mature IGF-1, which primarily drives differentiation of already-activated satellite cells. The sequential model suggests MGF acts first (proliferation) and IGF-1 acts second (differentiation).[3]

In vivo evidence is more limited. Animal studies have shown MGF expression increases following resistance exercise and correlates with subsequent muscle adaptation. However, direct evidence that exogenous PEG-MGF administration enhances muscle hypertrophy beyond normal training responses is lacking. Compare with IGF-1 LR3 and Follistatin for related muscle-focused peptide profiles, or see the Muscle Growth goal page.

Recovery & Sleep Context

MGF’s role as a damage-responsive peptide connects it to recovery research. The physiological trigger for MGF production — mechanical tissue stress — means it is inherently linked to repair processes following exercise or injury.[1]

Preclinical evidence suggests MGF may accelerate tissue repair timelines. Studies in neural tissue have demonstrated that IGF-1 and MGF promote neural stem cell activation and proliferation under conditions of hypoxia-ischaemia, inflammation, and oxidative stress, indicating repair-promoting activity beyond skeletal muscle.[5] In chondrocytes, MGF pretreatment attenuated osteoarthritis progression in animal models.[6]

Direct evidence linking PEG-MGF to recovery outcomes such as reduced muscle soreness, faster functional recovery, or improved sleep quality is absent. The recovery context is inferred from MGF’s role in tissue repair biology rather than demonstrated in recovery-specific endpoints. See the Recovery & Sleep goal page for broader context.

Injury & Tissue Support Context

The injury and tissue support research context is arguably the most physiologically aligned with MGF’s endogenous function. MGF is specifically upregulated in response to tissue damage, making it a natural component of the injury response cascade.[1]

Research in neuroprotection has shown MGF interacts with nucleolin to protect against cisplatin-induced neurotoxicity, demonstrating tissue-protective effects outside the musculoskeletal system.[7] Surface-modified electrospun fibres releasing MGF have been investigated for mitigating foreign-body reactions in biomedical implant contexts, suggesting potential applications in tissue engineering.[8]

The breadth of tissues responding to MGF — skeletal muscle, neural tissue, cartilage, periodontal ligament — suggests a more generalised role in tissue repair than initially understood. However, most of this evidence comes from cell culture and small animal studies. Compare with BPC-157 and TB-500 for related tissue repair peptide research, or see the Injury & Tissue Support goal page.

PEG-MGF Benefits

• Satellite cell activation: Research demonstrates MGF selectively activates quiescent satellite cells, expanding the available pool for muscle repair — a mechanism distinct from mature IGF-1.[1][3]
• Extended half-life: PEGylation extends biological activity from minutes to hours, enabling research protocols that native MGF’s rapid degradation would not permit.[2]
• Multi-tissue repair potential: Preclinical studies show MGF-mediated repair effects in skeletal muscle, neural tissue, cartilage, and periodontal ligament.[4][5][6]
• Neuroprotective properties: MGF has demonstrated protection against chemotherapy-induced neurotoxicity in preclinical models.[7]
• Distinct from systemic IGF-1: MGF acts locally at sites of tissue damage rather than systemically, potentially offering more targeted tissue effects.[1]

PEG-MGF Side Effects

Formal safety studies of PEG-MGF in humans have not been conducted. Side effect data is limited to preclinical observations and theoretical concerns:

• Injection site reactions: As with other PEGylated peptides, local injection site reactions are a theoretical concern, though not specifically documented for PEG-MGF.
• IGF-1 pathway concerns: As a derivative of the IGF-1 system, theoretical concerns about pro-proliferative effects on pre-existing pathological cells exist, though no evidence supports this risk specifically for MGF.
• PEG immunogenicity: Repeated exposure to PEGylated compounds can generate anti-PEG antibodies in some individuals, potentially reducing efficacy over time.
• No long-term data: The absence of chronic exposure studies means long-term safety implications remain entirely unknown.

Half-Life

Native MGF has an extremely short half-life — estimated at less than 10 minutes in plasma — due to rapid enzymatic degradation. This characteristic reflects MGF’s physiological role as a local, paracrine signal that acts at the site of tissue damage rather than systemically.[2]

PEGylation extends the functional half-life to several hours, though exact pharmacokinetic parameters vary depending on PEG chain size and study conditions. The extended half-life was the primary motivation for developing PEG-MGF as a research tool, allowing investigation of MGF biology at sustained exposure levels.

Limits of Current Evidence

• No human clinical data: PEG-MGF has not been tested in human clinical trials for any indication. All evidence derives from cell culture and animal models.
• Purity and characterisation concerns: As a research peptide without pharmaceutical development, batch-to-batch consistency and purity standardisation remain uncontrolled.
• Distinction from native MGF unclear: Whether PEGylated MGF replicates the spatial and temporal dynamics of endogenous MGF expression remains debated.
• Anti-doping context: MGF and PEG-MGF are on the World Anti-Doping Agency prohibited list, which has influenced the direction and publication of research.
• Limited dose-response data: Optimal concentrations for biological effects have not been systematically established.

Verdict

PEG-MGF represents an intellectually compelling research peptide — a stabilised form of the body’s own mechanically triggered repair signal. The underlying biology of MGF as a satellite cell activator is well-established and physiologically important. PEGylation solved a genuine technical problem by extending the peptide’s otherwise impractically short half-life.

However, the translational gap between MGF biology and PEG-MGF as a therapeutic tool remains wide. No human data exists, dose-response relationships are poorly defined, and the assumption that sustained exogenous exposure replicates the brief, localised endogenous signal may be flawed. The evidence base supports PEG-MGF as a useful research tool for studying growth factor biology, but confidence in its practical application should remain proportional to the predominantly preclinical data available.

FAQ

What is PEG-MGF peptide?

PEG-MGF is a PEGylated form of Mechano Growth Factor, an IGF-1 splice variant produced naturally when muscle tissue is mechanically stressed or damaged. The PEG modification extends the peptide’s otherwise very short half-life from minutes to hours, enabling research studies of its biological effects.

What is the difference between MGF and PEG-MGF?

Native MGF has a half-life of less than 10 minutes due to rapid enzymatic degradation. PEG-MGF attaches a polyethylene glycol chain to the peptide, extending its functional duration to several hours without altering its biological mechanism of action. PEG-MGF was developed primarily as a research tool.

What is mechano growth factor?

Mechano growth factor (MGF) is an alternative splice variant of the IGF-1 gene, also known as IGF-1Ec in humans. It is produced locally in muscle tissue in response to mechanical loading or damage and activates satellite cells — the stem cells responsible for muscle repair and regeneration.

How does PEG-MGF differ from IGF-1 LR3?

Both are modified forms of IGF-1, but they represent different variants. IGF-1 LR3 is a long-acting version of mature, systemic IGF-1 that drives cell differentiation. PEG-MGF is a stabilised version of the locally produced splice variant that activates satellite cell proliferation. They act at different stages of the tissue repair process.

Is PEG-MGF the same as IGF-1?

No. While MGF derives from the same gene as IGF-1, it is a distinct splice variant with a different peptide sequence (the Ec domain) and different biological activity. MGF activates satellite cell proliferation, while mature IGF-1 primarily drives differentiation. PEG-MGF is a further modification with an added PEG chain for stability.

Has PEG-MGF been tested in humans?

No human clinical trials of PEG-MGF have been conducted. All research data derives from cell culture studies and animal models. The peptide remains an investigational research compound with no approved clinical applications.

References

1. Kasprzak A. Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors. Int J Mol Sci. 2020. PMID: 32977489
2. Cox HD, et al. Detection of insulin analogues and large peptides >2 kDa in urine. Drug Test Anal. 2022. PMID: 35261185
3. Liu Y, et al. The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim Biophys Sin. 2023. PMID: 37171185
4. Feng F, et al. Mechano-growth factor regulates periodontal ligament stem cell proliferation and differentiation through Fyn-RhoA-YAP signalling. Biochem Biophys Res Commun. 2024. PMID: 39067248
5. Sha Y, et al. The Roles of IGF-1 and MGF on Nerve Regeneration under Hypoxia-Ischemia, Inflammation, Oxidative Stress, and Physical Trauma. Curr Protein Pept Sci. 2023. PMID: 36503467
6. Sha Y, et al. Pretreatment with mechano growth factor E peptide attenuates osteoarthritis. Int Immunopharmacol. 2021. PMID: 34015701
7. Podratz JL, et al. Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity. Exp Neurol. 2020. PMID: 32511954
8. Song Y, et al. Surface modification of electrospun fibers with mechano-growth factor for mitigating the foreign-body reaction. Bioact Mater. 2021. PMID: 33732968

LL-37 is the only cathelicidin-family antimicrobial peptide identified in humans.[2][7] Its name reflects its structure: 37 amino acid residues beginning with two leucine (L) residues. The peptide is produced as the C-terminal fragment of human cationic antimicrobial peptide 18 (hCAP18), encoded by the CAMP gene (cathelicidin antimicrobial peptide). Proteolytic cleavage — primarily by proteinase 3 in neutrophils — releases the biologically active LL-37 form from the cathelin-domain precursor.[1][2]

Structurally, the ll-37 peptide adopts an amphipathic α-helical conformation in membrane-mimetic and physiological environments, with a molecular weight of approximately 4,493.3 g/mol. This helical structure creates distinct hydrophobic and hydrophilic faces, which is central to its membrane-active properties — allowing it to interact with both microbial and host cell membranes depending on concentration, lipid composition, and environmental context.[2][7]

Expression of LL 37 occurs constitutively in neutrophil specific granules and is inducible in macrophages, epithelial cells lining the respiratory and gastrointestinal tracts, and skin keratinocytes. The peptide is also found in body fluids including sweat, saliva, and wound fluid at concentrations ranging from low micromolar to high micromolar levels during active infection or inflammation. Critically, CAMP gene expression is directly regulated by vitamin D through the vitamin D receptor (VDR), creating a well-documented mechanistic link between vitamin D status and innate antimicrobial capacity — a connection explored further below.[5][1]

Compound Profile

Mechanism of Action

The mechanism of action of the ll-37 peptide operates through two principal pathways: direct antimicrobial killing and host immunomodulation — a combination that distinguishes it from most conventional antimicrobial agents.[1][2][7]

Direct antimicrobial activity. LL-37’s amphipathic α-helix inserts into microbial membranes, creating pores and disrupting membrane integrity to cause pathogen lysis. This carpet-model and toroidal-pore mechanism is effective against Gram-positive and Gram-negative bacteria, certain enveloped viruses, and fungi. Unlike conventional antibiotics targeting specific metabolic pathways, this physical membrane-disruption approach makes resistance development substantially more difficult for pathogens — a property driving considerable research interest given the global antimicrobial resistance crisis.[2][7]

Immunomodulatory signalling. Beyond direct killing, LL 37 acts as a versatile immune signalling molecule through multiple receptor interactions. It binds formyl peptide receptor-like 1 (FPRL1/FPR2) to promote chemotaxis of neutrophils, monocytes, and T cells to sites of infection or injury. It modulates NF-κB signalling, influences cytokine release profiles (both pro- and anti-inflammatory depending on context), and can neutralise bacterial lipopolysaccharide (LPS) to dampen excessive inflammatory responses.[1][6][7]

Additionally, LL-37 interacts with purinergic receptors (P2X7) on immune cells, triggering IL-1β release and inflammasome activation — mechanisms relevant to both antimicrobial defence and inflammatory disease pathology.[1][6]

The peptide also promotes angiogenesis through VEGF-related pathways and stimulates keratinocyte migration — properties that connect its antimicrobial function to wound-healing activity.[3][1] Research into LL-37’s neuroprotective potential has explored its capacity to modulate neuroinflammatory pathways through mTOR-dependent mitochondrial protection mechanisms.[8]

Antimicrobial Research

The ll-37 antimicrobial profile is notably broad-spectrum. In vitro and animal model studies demonstrate activity against clinically relevant pathogens including Staphylococcus aureus (including methicillin-resistant strains), Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and mycobacterial species.[2][7]

Research has also explored LL-37’s capacity to disrupt bacterial biofilms — structured microbial communities embedded in extracellular matrix that are characteristically resistant to conventional antibiotic therapy. Biofilm disruption is considered mechanistically distinct from planktonic (free-floating) bacterial killing and represents an area of active investigation in chronic wound management and device-associated infection research. LL-37 appears to interfere with biofilm formation at sub-antimicrobial concentrations, suggesting potential utility as a biofilm-prevention strategy rather than solely a bactericidal agent.[2][7]

The antimicrobial peptide’s activity is concentration-dependent and influenced by ionic conditions, with physiological salt concentrations partially reducing its efficacy in some in vitro systems. This salt sensitivity — a common limitation among cationic antimicrobial peptides — has driven research into modified LL-37 analogues and truncated fragments with improved stability and activity profiles under physiological conditions.[2][7]

A distinct area of interest is LL-37’s potential synergy with conventional antibiotics. Some preclinical studies suggest that sub-inhibitory concentrations of the peptide can enhance the efficacy of standard antibiotics against resistant strains, though this remains an early-stage research observation rather than an established therapeutic strategy.[2][7]

It is important to note that most ll-37 antimicrobial data derives from in vitro assays and animal infection models. Translation to clinical antimicrobial applications remains at an early research stage, and LL-37 is not established as a therapeutic antimicrobial agent. The gap between promising in vitro activity and practical clinical utility represents the central challenge in this research area.

Wound Healing & Tissue Repair

Heilborn et al. (2003) provided foundational evidence that LL-37 is actively involved in human skin wound re-epithelialisation. Their study demonstrated that the cathelicidin peptide is upregulated in acute wound epithelium but notably absent in chronic, non-healing ulcers — suggesting a functional role in normal wound closure processes and identifying cathelicidin deficiency as a potential contributing factor in impaired wound healing.[3]

The wound-healing mechanisms attributed to LL 37 in preclinical research include:

• Keratinocyte migration and proliferation: LL-37 stimulates epithelial cell movement to wound sites through EGFR transactivation and supports the proliferative responses necessary for re-epithelialisation. This effect has been demonstrated in both scratch-wound assays and more complex organotypic skin models.[3][1]
• Angiogenesis promotion: the peptide promotes new blood vessel formation through VEGF-dependent and FPRL1-mediated pathways, supporting the nutrient and oxygen delivery critical to healing tissue. This pro-angiogenic activity connects LL-37’s wound-healing function to its involvement in rosacea pathology (discussed below).[1][7]
• Extracellular matrix remodelling: LL-37 influences matrix metalloproteinase (MMP) activity and tissue inhibitor of metalloproteinase (TIMP) balance, contributing to the structural reorganisation required during the proliferative and remodelling phases of tissue repair.[1]
• Inflammatory modulation at wound sites: by balancing pro- and anti-inflammatory signalling — including LPS neutralisation and selective cytokine suppression — LL-37 may help prevent the chronic inflammatory state that characterises non-healing wounds and is associated with delayed tissue repair.[1][6]

These tissue-repair properties overlap with the mechanisms studied in other peptides such as BPC-157 (gastric-derived repair signalling) and TB-500 (thymosin beta-4 fragment), though each operates through distinct molecular pathways and receptor systems. For broader context on tissue-repair peptide research, see the Injury & Tissue Support goal page.

Vitamin D & LL-37 Connection

One of the most significant discoveries in cathelicidin biology is the direct regulatory link between vitamin D and LL-37 expression — a finding that fundamentally connected nutritional immunology to antimicrobial peptide biology. Liu et al. (2006), publishing in Science, demonstrated that Toll-like receptor activation triggers a vitamin D-dependent antimicrobial pathway: TLR2/1 stimulation by mycobacterial lipopeptides upregulates both the vitamin D receptor (VDR) and the enzyme CYP27B1 (1α-hydroxylase), which converts circulating 25-hydroxyvitamin D to its active hormonal form (1,25-dihydroxyvitamin D). Active vitamin D then binds VDR to directly induce transcription of the CAMP gene encoding hCAP18/LL-37.[5]

This mechanism has substantial implications for understanding immune competence in relation to vitamin D status. Individuals with insufficient vitamin D levels (below approximately 30 ng/mL of 25-hydroxyvitamin D) show a reduced capacity to upregulate LL-37 in response to infection signals. The finding provided a compelling mechanistic explanation for the long-observed epidemiological association between vitamin D deficiency and increased susceptibility to infections, particularly tuberculosis — and offered a molecular rationale for the historical use of cod liver oil and sunlight in tuberculosis management.[5]

The vitamin D–LL 37 axis has been explored as a potential target for immune support strategies, particularly in populations with high prevalence of vitamin D insufficiency. Seasonal variation in vitamin D levels has been proposed as one contributing factor to winter infection susceptibility patterns, partly through reduced cathelicidin expression.[5] However, whether vitamin D supplementation reliably enhances LL-37-mediated antimicrobial responses in clinical settings remains an active area of investigation, with intervention trials producing mixed results to date.

LL-37 in Skin Conditions

The role of cathelicidin in skin health is complex and, in some conditions, paradoxical. While LL-37 contributes to normal skin barrier defence and wound repair, aberrant processing and overexpression are implicated in inflammatory skin conditions.[4]

Rosacea. Yamasaki et al. (2007) published landmark findings in Nature Medicine demonstrating that rosacea skin exhibits both elevated cathelicidin levels and abnormal proteolytic processing by kallikrein 5 (KLK5). In healthy skin, cathelicidin is processed to generate LL-37 with balanced antimicrobial and immunomodulatory activity. In rosacea, aberrant KLK5 overactivity generates different cathelicidin fragments with enhanced pro-inflammatory and pro-angiogenic activity compared to native LL-37, directly contributing to the erythema, persistent inflammation, and telangiectasia (visible blood vessel changes) characteristic of rosacea subtypes.[4]

Psoriasis. LL-37 has been identified as a potential autoantigen in psoriasis. The peptide can form complexes with self-DNA, activating plasmacytoid dendritic cells through TLR9 and driving the interferon-alpha response implicated in psoriatic inflammation.[6]

Atopic dermatitis. In contrast to rosacea and psoriasis, atopic dermatitis is associated with relative cathelicidin deficiency in lesional skin, which may contribute to the increased susceptibility to skin infections (particularly S. aureus colonisation) observed in this condition. This finding has prompted investigation into whether boosting LL-37 expression — for example through vitamin D pathways — might support barrier function in atopic skin.[1][5]

For broader skin-related peptide research, the GHK-Cu profile covers copper peptide signalling in skin remodelling contexts.

Immunomodulatory Properties

The ll-37 immune profile extends well beyond simple antimicrobial killing. The peptide functions as an endogenous immune modulator with the capacity to bridge innate and adaptive immune responses.[1][6]

Key immunomodulatory functions documented in preclinical research include:

• Chemotaxis: LL-37 recruits neutrophils, monocytes, and T cells to sites of infection or tissue damage through FPRL1/FPR2 receptor signalling.[1][2]
• Cytokine modulation: the peptide can both stimulate and suppress cytokine production depending on context — promoting pro-inflammatory responses during acute infection while dampening excessive inflammation in other settings through LPS neutralisation.[1][6]
• Dendritic cell activation: LL-37 influences dendritic cell maturation and antigen presentation, creating a functional bridge between innate pathogen detection and adaptive immune activation.[1][6]
• Mast cell degranulation: the peptide can trigger histamine release from mast cells, contributing to local inflammatory and vascular responses.[1]
• NF-κB pathway modulation: LL 37 modulates the NF-κB signalling cascade, a central regulatory pathway in inflammatory gene expression.[1][7]

Kahlenberg and Kaplan (2013) provided a comprehensive review of LL-37’s dual role in inflammation and autoimmunity, highlighting that the same immunomodulatory properties that provide protection against infection can, in certain contexts, contribute to autoimmune pathology — particularly in systemic lupus erythematosus (SLE) and psoriasis.[6]

Research into neuroprotective applications has explored LL-37’s capacity to modulate neuroinflammation, with preclinical evidence suggesting protective effects through mTOR-dependent mitochondrial mechanisms and reduction of neuronal apoptosis under inflammatory stress conditions.[8] These findings remain early-stage but contribute to the broader interest in antimicrobial peptides as multifunctional immune-neural mediators. For related neuroprotection research, see the Semax and Selank profiles, plus the Neuroprotection goal page for broader context.

Side Effects & Safety Profile

The ll-37 side effects profile is primarily characterised by concentration-dependent cytotoxicity and potential immunogenicity concerns documented in preclinical research.[2][7]

Cytotoxicity. At elevated concentrations, LL-37’s membrane-active mechanism does not discriminate perfectly between microbial and host cell membranes. In vitro studies demonstrate dose-dependent toxicity to mammalian cells, including red blood cells (haemolysis), at concentrations substantially above those associated with antimicrobial activity.[2][7]

Immunogenicity. As an endogenous human peptide, LL 37 is expected to have lower immunogenicity than foreign peptides. However, its capacity to form immunogenic complexes with self-nucleic acids (as demonstrated in psoriasis and lupus research) introduces considerations about potential autoimmune activation in susceptible individuals.[6]

Pro-inflammatory potential. The same immunomodulatory properties that provide defence can produce unwanted inflammation. Mast cell degranulation, excessive cytokine release, and pro-angiogenic activity represent potential adverse effects depending on context and concentration.[1][4]

Protease degradation. LL-37 is susceptible to rapid degradation by endogenous proteases, which limits its systemic exposure but also complicates delivery and dosing in research contexts.[2][7]

No standardised safety data from controlled human clinical trials exists for exogenous LL-37 administration. All safety inferences derive from in vitro studies, animal models, and observational data on endogenous LL-37 biology. The peptide is a research compound and is not approved for therapeutic use. Researchers investigating LL-37 analogues have focused on separating the beneficial antimicrobial activity from the host-cell cytotoxicity through structural modifications, with some success in preclinical models.[2][7]

Pharmacokinetics

The pharmacokinetic profile of LL-37 presents significant challenges for research applications. The peptide’s half-life has not been fully characterised in systematic pharmacokinetic studies, though it is understood to be subject to rapid proteolytic degradation in biological environments.[2][7]

Stability. LL 37 is susceptible to cleavage by multiple endogenous proteases, including those present in serum, at wound sites, and in the gastrointestinal tract. This protease susceptibility limits its persistence and bioavailability following administration and represents a major hurdle for any therapeutic development. Serum half-life estimates remain poorly defined, though degradation in plasma appears rapid relative to synthetic drug-like peptides.[2][7]

Salt sensitivity. The peptide’s antimicrobial activity is reduced under physiological ionic conditions (approximately 150 mM NaCl), which affects its functional efficacy in vivo. This has prompted research into modified analogues and D-amino acid substituted variants with improved salt tolerance and protease resistance.[2]

Delivery challenges. The combination of protease susceptibility, salt sensitivity, and molecular size (37 amino acids, ~4.5 kDa) creates delivery challenges that have driven investigation into nanoparticle encapsulation, liposomal formulations, modified analogues, and localised delivery approaches (including wound dressings and topical preparations) in preclinical research settings.[7]

Distribution. Endogenous LL-37 is found at highest concentrations at epithelial barrier surfaces (skin, respiratory tract, gastrointestinal tract) and in neutrophil-rich inflammatory exudates. Circulating plasma concentrations are generally lower, reflecting its primary role as a local defence molecule with localised immunomodulatory signalling rather than systemic pharmacological activity.[1][2]

FAQ

What is LL-37?

LL-37 (also written LL 37) is the only human cathelicidin antimicrobial peptide — a 37-amino-acid defence molecule produced by immune cells and epithelial tissues. It is the active fragment of the precursor protein hCAP18, encoded by the CAMP gene. Research interest centres on its dual antimicrobial and immunomodulatory properties.[1][2]

What are the researched benefits of LL-37?

Preclinical research into ll-37 benefits spans antimicrobial defence (broad-spectrum pathogen killing and biofilm disruption), wound healing support (keratinocyte migration, angiogenesis), immunomodulation (cytokine regulation, chemotaxis), and emerging neuroprotection investigations. All evidence derives primarily from in vitro and animal studies.[1][2][3][7]

How does vitamin D affect LL-37 levels?

Vitamin D directly regulates LL-37 production through the vitamin D receptor (VDR). Active vitamin D (1,25-dihydroxyvitamin D) binds VDR to induce CAMP gene transcription, increasing hCAP18/LL-37 expression. This mechanism links vitamin D status to innate antimicrobial capacity.[5]

Is LL-37 the same as cathelicidin?

LL-37 is the active peptide form of the human cathelicidin. Cathelicidins are a family of antimicrobial peptides found across vertebrate species, but LL 37 is the only member identified in humans. The precursor protein is called hCAP18; LL-37 is the 37-residue fragment released by proteolytic cleavage.[2][7]

What is the connection between LL-37 and rosacea?

Rosacea skin shows elevated levels of cathelicidin that is abnormally processed by the enzyme kallikrein 5 (KLK5), generating modified peptide fragments with enhanced pro-inflammatory and pro-angiogenic activity. This contributes directly to rosacea symptoms including redness, inflammation, and visible blood vessels.[4]

What are the side effects of LL-37?

The ll-37 side effects documented in preclinical research include concentration-dependent cytotoxicity to host cells, potential for excessive immune activation, mast cell degranulation, and theoretical autoimmune concerns related to self-nucleic acid complex formation. No controlled human safety data from clinical trials is available.[2][6][7]

Is LL-37 FDA approved?

No. LL-37 is not approved by the FDA or any regulatory agency for therapeutic use. It remains a research compound studied in preclinical contexts. All references to its properties on this page describe findings from laboratory and animal model investigations, not established clinical applications.

How does LL-37 differ from other antimicrobial peptides?

LL-37 is distinguished by being the only human cathelicidin, its amphipathic α-helical structure, and its unusually broad functional profile combining direct membrane-disrupting antimicrobial activity with extensive immunomodulatory, wound-healing, and potential neuroprotective properties. Most other antimicrobial peptides have narrower functional ranges.[2][7]

References

1. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22-35. doi:10.1016/j.cellimm.2012.11.009. PMID: 23246832
2. Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408-1425. doi:10.1016/j.bbamem.2006.03.030. PMID: 16716248
3. Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003;120(3):379-389. doi:10.1046/j.1523-1747.2003.12069.x. PMID: 12603850
4. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980. doi:10.1038/nm1616. PMID: 17676051
5. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-1773. doi:10.1126/science.1123933. PMID: 16497887
6. Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191(10):4895-4901. doi:10.4049/jimmunol.1302005. PMID: 24185823
7. Xhindoli D, Pacor S, Benincasa M, Scocchi M, Gennaro R, Tossi A. The human cathelicidin LL-37 — A pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta. 2016;1858(3):546-566. doi:10.1016/j.bbamem.2015.11.003. PMID: 26556394
8. Sun W, Zheng Y, Lu Z, et al. LL-37 attenuates inflammatory impairment via mTOR signaling-dependent mitochondrial protection. Int J Biochem Cell Biol. 2014;54:26-35. doi:10.1016/j.biocel.2014.06.015. PMID: 24984264

If your query is what is bpc-157 (or what is bpc 157), the practical answer is: BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid fragment derived from a protective protein found in human gastric juice — studied primarily in tissue-recovery, wound-healing, and musculoskeletal repair research contexts.[1][2][3] It is sometimes referred to as the wolverine peptide due to its association with accelerated healing signals in preclinical models.

In plain language, BPC-157 peptide (also written as BPC 157 peptide, bp 157 peptide, or bcp157) is usually interpreted as a recovery-continuity support candidate with strong preclinical evidence but limited human clinical data. Most interest centres on whether it can support more predictable recovery from soft-tissue stress — tendons, ligaments, muscles, and gut-related contexts.[1][4][5]

This page should be read alongside the TB-500 profile (the most common comparison peptide), the BPC-157 vs TB-500 side-by-side comparison, and the Injury & Tissue Support and Recovery & Sleep goal pages for broader context.

Compound Profile

What Does BPC-157 Actually Do?

BPC-157 is usually evaluated through a stability and recovery lens. The key question for BPC-157 benefits is whether irritation-to-function trends improve enough to reduce stop-start training or rehab cycles — not whether it produces overnight structural repair.

Useful practical markers include:

• Irritation-to-function trend: previously sensitive areas (tendons, joints, connective tissue) becoming more manageable under progressive load.
• Recovery smoothness: fewer hard rebound days after demanding sessions — the core of bpc 157 benefits in real-world interpretation.
• Routine adherence: improved ability to keep training or rehab frequency stable without forced rest days.
• Movement confidence: better trust in repeatable movement quality over multi-week blocks.

Best interpreted as continuity support, not overnight transformation. The preclinical evidence base is substantial, but human clinical data remains early-stage.[3][5][6]

How BPC-157 Works

BPC-157 is commonly discussed in relation to multiple healing-related pathways: angiogenesis (new blood vessel formation), nitric oxide signalling, growth factor modulation (including VEGF, FGF, and EGF pathways), and tendon outgrowth promotion.[1][2][4][7]

The mechanistic picture from preclinical research suggests BPC-157 may create a more favourable healing environment by upregulating growth factor expression, promoting cell survival and migration at injury sites, and supporting collagen organisation in connective tissue.[4][7] A 2025 systematic review in orthopaedic sports medicine confirmed consistent preclinical findings across tendon, ligament, muscle, and bone models — but emphasised the gap between animal model evidence and human clinical validation.[5]

In practice, signal interpretation is strongest when sleep, rehab structure, load progression, and nutrition are controlled. Without baseline control, confidence in attributing outcomes to any single compound drops quickly. Mechanistic plausibility does not equal guaranteed outcome in every real-world context.[3][6]

Injury & Tissue Support Context

The strongest evidence cluster for BPC-157 falls within Injury & Tissue Support. Preclinical models consistently show accelerated healing signals across multiple tissue types — tendons, ligaments, muscles, and gastrointestinal mucosa.[1][2][4][5] The 2025 HSS Journal systematic review specifically highlighted BPC-157’s emerging relevance in orthopaedic and sports medicine contexts, noting positive signals for tendon-to-bone healing and soft-tissue repair.[5]

The most useful distinction is repair-support context versus repair guarantee. BPC-157 belongs in the first category. When users reference BPC-157 benefits for injury recovery, the defensible framing is improved recovery conditions — better movement tolerance, fewer interruptions, and steadier return-to-activity behaviour — not guaranteed structural restoration for every user or tissue type.[3][5][6]

Practical value is often whether small tissue setbacks become less disruptive over time, allowing better continuity in structured rehab or training blocks. This is best judged by week-level function and tolerance trends, not isolated day-to-day fluctuations. For comparison with the other major recovery peptide, see BPC-157 vs TB-500.

Recovery & Sleep Context

Recovery and sleep relevance with BPC-157 is usually indirect: when irritation and movement tolerance improve, training stress is often easier to manage, which can support more stable sleep and recovery patterns. This is the Recovery & Sleep pathway — not a direct sedative or sleep-aid mechanism.

In practical terms, users often interpret this as fewer disrupted training weeks, smoother bounce-back between sessions, and less cumulative fatigue from stop-start injury cycles. The brain-gut axis research also suggests BPC-157 may interact with neurotransmitter activity — including serotonin, dopamine, and GABA pathways — though this remains largely preclinical and exploratory.[8][9]

The strongest interpretation is trend-based consistency over time, not acute overnight effects. Compare with TB-500 for an alternative recovery-focused peptide profile, or see the broader Recovery & Sleep goal page for cluster context.

BPC-157 Benefits

Most BPC-157 benefits and BPC 157 benefits discussions are strongest when interpreted as continuity and recovery outcomes rather than dramatic transformation claims:

• Accelerated soft-tissue recovery signals: consistent preclinical evidence for tendon, ligament, muscle, and gut healing support.[1][2][4][5]
• Improved training continuity: fewer forced rest days and less stop-start disruption in structured programmes.
• Better movement confidence: improved trust in repeatable movement quality under progressive load.
• Angiogenesis support: promotion of new blood vessel formation, which may support healing-environment quality at injury sites.[2][7]
• Gastroprotective properties: the “body protection compound” origin — preclinical evidence for gut mucosa protection and healing, including ulcer and fistula models.[1][10]
• Neuroprotective signals: emerging preclinical data on brain-gut axis interactions and CNS-related recovery contexts.[8][9]

Evidence-weighted read: support-pattern outcomes are plausible and well-replicated in animal models, but human clinical certainty remains limited. A 2025 pilot study on IV BPC-157 in humans reported a favourable safety profile but was not powered for efficacy endpoints.[6]

BPC-157 Side Effects

For both BPC-157 side effects and BPC 157 side effects intent, the evidence base is primarily preclinical, supplemented by limited human safety data. A 2025 pilot study on intravenous BPC-157 administration in humans reported no serious adverse events, but the sample size was small.[6]

Commonly discussed issues include:

• Nausea or GI discomfort: reported anecdotally, particularly at higher amounts or with certain administration approaches.
• Headache patterns: inconsistently reported, with unclear attribution given confounding variables.
• Administration-site irritation: localised discomfort reported in anecdotal contexts.
• High person-to-person variability: response profiles differ significantly between individuals, making generalisation difficult.
• Misattribution risk: when multiple recovery inputs change simultaneously (sleep, nutrition, training load, physio), side effect attribution to BPC-157 specifically becomes unreliable.

The preclinical safety profile is generally favourable across a wide range of studies, with no reported organ toxicity or significant adverse effects in animal models.[1][3] However, human evidence depth is still insufficient for definitive safety conclusions. Practical confidence should stay proportional to data quality.

Half-Life

For BPC-157 half-life (also searched as BPC 157 half life) queries: the pharmacokinetic profile of BPC-157 is not fully characterised in published human studies. Preclinical data suggests relatively rapid clearance, but public half-life claims vary widely by source and format — and certainty is often overstated in community discussion.

What is established: BPC-157 demonstrates notable stability in gastric juice (unusual for a peptide of this size), which is relevant to its origin as a gastric pentadecapeptide and to research exploring various administration approaches.[1][3]

Practical interpretation is usually stronger when tied to weekly recovery trends rather than exact timing assumptions. Use half-life as orientation only; use multi-week trend quality for decisions.

Limits of Current Evidence

• Preclinical dominance: the vast majority of BPC-157 evidence comes from animal models (primarily rats). Mechanistic signals are consistent and well-replicated, but direct human translation is unconfirmed for most endpoints.[3][5][6]
• Limited human data: only one published human safety pilot (2025, IV administration) — not powered for efficacy. No Phase II or Phase III clinical trials completed as of mid-2026.[6]
• Tissue-type variability: not all recovery narratives generalise across tissue types. Tendon evidence is stronger than muscle or bone evidence in the preclinical literature.[5]
• Self-reported outcomes: anecdote-heavy interpretation should be treated as low confidence — expectation bias and concurrent treatment changes are common confounders.
• Regulatory status: BPC-157 is not FDA-approved for any indication. It is classified as a research compound.
• Publication concentration: a significant portion of published research originates from a single research group, which warrants acknowledgement when evaluating evidence breadth.[3]

Verdict

BPC-157 fits best as a recovery-continuity candidate for contexts where reducing soft-tissue disruption and improving movement confidence over time are the primary goals. The preclinical evidence base is among the most extensive for any recovery-focused peptide, with consistent signals across tendon, ligament, muscle, gut, and emerging CNS models.[1][2][4][5]

It is usually a weaker fit for “fast dramatic change” expectations. Practical value tends to be highest when fundamentals (sleep, nutrition, structured rehab, load management) are already disciplined and outcomes are judged by multi-week trend quality rather than day-to-day fluctuations.

The critical caveat remains the gap between preclinical signal strength and human clinical validation. Until larger human trials are completed, confidence should stay proportional to evidence depth. For navigation, anchor this profile to the Injury & Tissue Support and Recovery & Sleep goal pages, and pressure-test with the BPC-157 vs TB-500 comparison and the TB-500 profile.

FAQ

What is BPC-157 used for in research?

BPC-157 is primarily studied in tissue-recovery and wound-healing contexts — including tendon, ligament, muscle, gut mucosa, and emerging CNS models. Preclinical research consistently shows accelerated healing signals, but human clinical trials are still in early stages. It is classified as a research compound, not an approved therapeutic.[1][3][5]

Does BPC-157 support tissue repair, or is that overstated?

Support-context framing is reasonable; guaranteed-repair framing is not. Preclinical evidence across multiple tissue types is consistent and well-replicated, but human translation remains unconfirmed for most endpoints. Keep interpretation conservative and trend-based.[5][6]

BPC-157 vs TB-500: what is the useful comparison angle?

Both are recovery-focused peptides, but they work through different mechanisms. BPC-157 is associated with angiogenesis, growth factor modulation, and gastric-origin tissue protection. TB-500 (Thymosin Beta-4 fragment) acts primarily through actin regulation and cell migration. The variant phrasings BPC-157 and TB-500, BPC 157 and TB500, and BPC 157 TB 500 all point to the same comparison — see BPC-157 vs TB-500 for the full side-by-side analysis.

Is BPC-157 the “wolverine peptide”?

The wolverine peptide nickname comes from BPC-157’s association with accelerated healing signals in preclinical research. While the nickname is catchy, it overstates current evidence — preclinical tissue-repair support is not the same as superhuman regeneration. The name persists in community discussion but should be interpreted with appropriate scepticism.

What are BPC-157 side effects?

Commonly discussed BPC 157 side effects include nausea, GI discomfort, headache, and administration-site irritation — though these are primarily anecdotal. A 2025 human safety pilot reported no serious adverse events, but the sample size was small. The preclinical safety profile is generally favourable, with no reported organ toxicity across extensive animal studies.[1][3][6]

Is BPC-157 backed by strong human evidence?

Not yet. Preclinical evidence is extensive and consistent, but only one published human study exists (a 2025 IV safety pilot). No Phase II or Phase III clinical trials have been completed. Confidence should stay proportional to this evidence gap.[3][5][6]

BPC-157 dose and BPC-157 dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Dose and dosage intent is valid, but this profile focuses on mechanism context, evidence quality, and risk-aware interpretation. BPC-157 is a research compound — not an approved therapeutic — and dosing information should be sought from qualified researchers or healthcare providers.

Does BPC-157 help with gut health?

BPC-157 originates from a gastric juice protein, and preclinical research shows consistent gastroprotective signals — including ulcer healing, fistula repair, and gut mucosa protection models.[1][10] However, human gut-health evidence is limited and mostly extrapolated from the compound’s origin and animal data. The brain-gut axis research is emerging but still exploratory.[8][9]

Can BPC-157 help with hair growth?

There is limited preclinical evidence suggesting BPC-157 may support hair follicle health through its angiogenic and growth-factor pathways, but BPC 157 hair growth claims should be treated as speculative. No dedicated hair-growth studies have been published, and any such effects would be indirect at best.

What should be tracked weekly to interpret BPC-157 signal?

Track soreness trend, movement tolerance under load, training continuity (missed sessions), and overall recovery consistency. Week-level logs are usually more informative than daily interpretation. Define markers before starting and review them at consistent intervals to reduce confirmation bias.

References

1. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654. PubMed.
2. Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550. PubMed.
3. Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PubMed.
4. Krivic A, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29998800. PubMed.
5. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. PubMed.
6. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PubMed.
7. Staresinic M, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):811-820. PMID: 21030672. PubMed.
8. Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887. PubMed.
9. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel). 2023;16(5):676. PMID: 37242459. PubMed.
10. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3338. PMID: 36551977. PubMed.

If your query is what is tb-500, the practical answer is: TB-500 is a synthetic peptide fragment corresponding to the active region (amino acids 17-23) of thymosin beta-4, a naturally occurring 43-amino-acid protein involved in cell migration, wound healing, and tissue repair signalling.[1][2]

In plain language, tb-500 peptide (also written as tb 500 or tb500) is studied primarily through a recovery and tissue-repair lens. Thymosin beta-4 is one of the most abundant intracellular proteins in mammalian cells, where it plays a central role in actin polymerisation, cell motility, and tissue remodelling. TB-500 replicates the region of thymosin beta-4 responsible for its actin-binding and cell-migration properties.[1][3]

The research profile spans wound healing, cardiac repair, corneal injury, hair follicle activation, and anti-inflammatory activity. Animal data is extensive and directionally consistent. Human clinical data is limited but emerging, with a 2025 cardiac study providing the first controlled human evidence.[4] For adjacent context, this page pairs naturally with BPC-157 and the BPC-157 vs TB-500 comparison.

Compound Profile

What Does TB-500 Actually Do?

TB-500 is usually evaluated through a recovery-continuity lens. The core action centres on actin regulation: TB-500 sequesters G-actin monomers, promoting the formation of new actin filaments that drive cell migration to injury sites. This is the mechanistic foundation for its tissue-repair signals across multiple organ systems.[1][3]

Useful practical markers from the literature include:

• Wound closure acceleration: faster epithelialisation and granulation tissue formation in dermal, corneal, and cardiac wound models.[3][5][6]
• Cardiac tissue repair: improved ventricular function and reduced scar size in ischaemic heart models, with the first human cardiac data published in 2025.[4][7]
• Anti-inflammatory activity: downregulation of pro-inflammatory cytokines and modulation of inflammatory cell infiltration at injury sites.[2][8]
• Hair follicle activation: thymosin beta-4 stimulates hair growth via stem cell migration and differentiation in mouse models.[9][10]
• Corneal wound healing: accelerated corneal epithelial repair and reduced inflammation following chemical injury, with human clinical interest in ophthalmology.[5][6]

Best framed as support-context for recovery rhythm across tissue types, not a guaranteed structural repair tool. The breadth of tissue responses is notable but the depth of human evidence remains limited.

How TB-500 Works

TB-500 is a synthetic fragment of thymosin beta-4, replicating the 17-23 amino acid sequence (LKKTETQ) that mediates its biological activity. The parent protein thymosin beta-4 is one of the most studied members of the beta-thymosin family and plays fundamental roles in cellular architecture and tissue repair.[1][2]

Key mechanisms identified in the literature:

• Actin polymerisation regulation: TB-500 sequesters G-actin monomers, controlling the balance between monomeric and filamentous actin. This drives cell migration, a prerequisite for wound healing and tissue remodelling in every tissue type studied.[1][3]
• Cell migration promotion: by modulating the actin cytoskeleton, TB-500 promotes directional migration of endothelial cells, keratinocytes, and cardiac progenitor cells toward injury sites.[3][4]
• Angiogenesis: stimulates new blood vessel formation via endothelial cell migration and VEGF-related pathways, supporting nutrient and oxygen delivery to healing tissues.[3][7]
• Anti-inflammatory signalling: downregulates NF-κB-mediated inflammatory responses and reduces pro-inflammatory cytokine production, creating a more favourable environment for tissue repair.[2][8]
• Stem cell activation: in hair follicle models, thymosin beta-4 activates follicular stem cells and promotes their migration and differentiation.[9][10]

The interpretation point that matters: mechanism plausibility does not equal guaranteed outcome. TB-500 has strong mechanistic logic and consistent animal data, but signal quality in any individual context still depends on injury type, timing, and the broader recovery environment.

Injury and Tissue Support Context

Injury and tissue support is TB-500’s primary research domain and where the evidence base is deepest. The parent protein thymosin beta-4 has been studied across dermal wounds, cardiac ischaemia, corneal injury, tendon damage, and musculoskeletal repair models.[1][2][3]

Key findings across tissue types:

• Dermal wound healing: Philp et al. (2004) demonstrated that thymosin beta-4 promotes angiogenesis, accelerates wound closure, and enhances hair follicle development at wound sites in animal models.[3]
• Corneal repair: Sosne et al. (2002) showed thymosin beta-4 promotes corneal wound healing and decreases inflammation following alkali injury, a finding that led to sustained ophthalmological interest and human clinical exploration.[5] A 2025 engineered tandem thymosin peptide further advanced corneal healing outcomes.[6]
• Tendon and soft tissue: orthopaedic review literature identifies TB-500 as one of the most studied injectable peptides in sports medicine contexts, with signals across tendon healing, ligament repair, and soft-tissue recovery.[2]
• Musculoskeletal context: the 2026 orthopaedic review by Rahman et al. positioned thymosin beta-4 among the leading therapeutic peptide candidates for musculoskeletal applications based on cumulative preclinical evidence.[11]

When users say TB-500 “helps repair,” the defensible framing is that it supports the biological conditions for tissue remodelling: cell migration, angiogenesis, and inflammatory modulation. Not guaranteed structural restoration. The animal evidence is consistent and broad, but controlled human tissue-repair trials are only beginning to emerge.

Cardiac Repair Context

Cardiac repair is where TB-500 and thymosin beta-4 have generated the most translational excitement and, recently, the first human clinical data.

The preclinical foundation is substantial: Smart et al. (2007) established that thymosin beta-4 is essential for coronary vessel development and promotes neovascularisation via adult epicardial progenitor cells.[7] Maar et al. (2025) demonstrated thymosin beta-4 modulates cardiac remodelling by regulating ROCK1 expression in adult mammals, reducing fibrosis and improving ventricular function after injury.[8]

The breakthrough: Zhang et al. (2025) published in Cardiovascular Research the first controlled human evidence, showing recombinant human thymosin beta-4 improved ischaemic cardiac dysfunction in both mouse models and patients with acute ST-segment elevation myocardial infarction (STEMI). This is a significant milestone because it moves thymosin beta-4 cardiac research from animal-only to human translational evidence.[4]

Interpretation should stay measured: this is early-stage human data from a single study. But it represents the most advanced clinical evidence for any thymosin beta-4 application and validates the preclinical cardiac repair signals that have accumulated over two decades.

Recovery and Sleep Context

Recovery and sleep relevance for TB-500 is generally downstream: if tissue-stress recovery becomes more stable, total training disruption can fall, which may support steadier sleep quality and better next-session readiness.

In practice, this often appears as fewer interrupted training blocks, lower rebound fatigue, and more predictable recovery rhythm across demanding weeks. The anti-inflammatory mechanisms may contribute to reduced systemic inflammation burden, which can influence sleep architecture indirectly.[2][8]

The practical lens is continuity over time, not one-day symptom swings. For a recovery-focused comparison with the other primary tissue-repair peptide, see the BPC-157 vs TB-500 breakdown.

TB-500 Hair Growth Context

TB-500 hair growth is a consistently searched topic, and the parent protein thymosin beta-4 has genuine hair follicle research behind it.

Philp et al. (2004) demonstrated in FASEB Journal that thymosin beta-4 increases hair growth by activation of hair follicle stem cells.[10] The same group showed thymosin beta-4 promotes hair follicle development alongside angiogenesis and wound healing in animal models.[3] Gao et al. (2015) confirmed thymosin beta-4 induces mouse hair growth via stem cell migration pathways, and a 2016 follow-up explored the molecular mechanisms through which thymosin beta-4 drives follicle cycling.[9]

The evidence is consistent in animal models but no human hair growth trials exist for TB-500 or thymosin beta-4. The mechanistic logic is sound: the same stem cell migration and growth factor pathways that drive wound healing also support hair follicle activation. But translating mouse hair growth data to human outcomes requires caution. Hair growth is biologically plausible but clinically unconfirmed for TB-500.

TB-500 Benefits

TB-500 benefits are strongest when interpreted through evidence-weighted framing:

• Wound healing acceleration: consistent across dermal, corneal, and cardiac wound models in animals. The most replicated finding in the TB-500 literature.[3][5][6]
• Cardiac function improvement: reduced scar size and improved ventricular function in ischaemic models, with first-in-human STEMI data published 2025.[4][7][8]
• Anti-inflammatory activity: downregulation of pro-inflammatory cytokines and NF-κB signalling, creating more favourable repair conditions.[2][8]
• Hair follicle activation: stem cell migration and differentiation in mouse hair growth models. Consistent preclinical signals across multiple studies.[9][10]
• Corneal repair: accelerated epithelial healing and reduced inflammation in corneal injury models, with clinical ophthalmology interest.[5][6]
• Training continuity support: in the practical context, TB-500 is often evaluated by fewer stop-start disruptions, better movement confidence, and more consistent recovery rhythm across training blocks.

Evidence-weighted read: animal tissue-repair data is extensive and consistent. Human cardiac data is emerging. Other human clinical data remains limited. Support-pattern outcomes are plausible, but certainty remains context-dependent.[2][4]

TB-500 Side Effects

For tb-500 side effects intent, the safety profile draws primarily from animal studies and the limited human cardiac data:

• Headache patterns: reported in anecdotal contexts. Not systematically documented in controlled research.
• Nausea or GI discomfort: occasional reports in practical use contexts.
• Injection site reactions: redness, swelling, or discomfort at injection sites. Consistent with most subcutaneous peptide administration.
• Lethargy or fatigue: transient tiredness reported by some users, typically resolving within days.
• Substantial person-to-person variability: individual responses vary considerably, and attribution is difficult when multiple recovery variables change simultaneously.

The 2025 human cardiac study reported thymosin beta-4 was well tolerated in STEMI patients, though this was a specific clinical population receiving specific protocols.[4] Broader human safety profiling for TB-500 at various research concentrations remains limited. Trend-based interpretation over weeks is more reliable than single-day reactions.[2]

Half-Life

For tb-500 half-life queries: TB-500 is commonly discussed with a multi-day persistence context, often cited around 2 to 3 days in practical discussions. The equine pharmacokinetic analysis by Ho et al. (2012) characterised TB-500 detection windows in plasma and urine, providing the most detailed pharmacokinetic data available for this peptide.[12]

Exact human pharmacokinetic certainty is still limited. The peptide’s relatively long half-life compared to smaller peptides like GHK-Cu (which degrades in minutes to hours) is attributed to its larger size (4963 g/mol) and protein-like structure.

Practical takeaway: use half-life as orientation, then judge outcomes by weekly recovery and movement-trend quality rather than strict clock assumptions.

Neuroprotection Context

Neuroprotection is an emerging research area for thymosin beta-4 with recent significant findings. Ou et al. (2026) demonstrated that thymosin beta-4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro and in vivo models, suggesting neuroprotective potential through anti-inflammatory CNS pathways.[13]

This emerging neuroprotective profile parallels recent findings in the related peptide GHK-Cu, which has shown neuroprotective signals in Alzheimer’s mouse models. Both peptides share anti-inflammatory and tissue-protective mechanisms, though through distinct pathways. TB-500 neuroprotection data is currently limited to a single study and remains preclinical.

Limits of Current Evidence

• Animal data is extensive and consistent across wound healing, cardiac repair, corneal injury, and hair follicle activation. This breadth is unusual for a single peptide fragment.[1][2][3]
• Human evidence is emerging but limited. The 2025 cardiac STEMI study is the most significant clinical milestone, but it is a single study in a specific population.[4]
• Ophthalmological interest has not yet produced approved therapies. Despite two decades of corneal research, thymosin beta-4 eye treatments remain investigational.[5][6]
• Hair growth data is animal-only. Mouse studies are consistent but human hair trials do not exist.[9][10]
• Attribution weakens quickly when multiple recovery variables shift at once. Short-term perception can overstate confidence versus week-level data.
• Equine doping detection research provides pharmacokinetic data but was designed for regulatory detection, not therapeutic characterisation.[12]

Decision rule: confidence rises when the same pattern repeats under stable conditions. Animal evidence supports mechanism plausibility. Human evidence supports cardiac applications. Other applications remain preclinical.

Verdict

TB-500 is best positioned as a recovery-continuity support candidate with unusually broad preclinical evidence across wound healing, cardiac repair, corneal injury, hair follicle activation, and anti-inflammatory activity. The parent protein thymosin beta-4 has one of the longest and most consistent research trails in the peptide literature.

The 2025 human cardiac data marks a genuine translational milestone. For other applications, the evidence remains preclinical but mechanistically sound. TB-500 tends to fit best when fundamentals are already tight (sleep, load management, rehab structure, nutrition) and outcomes are judged by trend quality, not one-day noise.

For navigation, map this profile to Injury and Tissue Support and Recovery and Sleep, pressure-test with BPC-157 vs TB-500, and cross-reference with BPC-157 and GHK-Cu for the broader tissue-repair peptide landscape.

FAQ

What is TB-500?

TB-500 is a synthetic peptide fragment of thymosin beta-4, a naturally occurring protein involved in cell migration, wound healing, and tissue repair. It corresponds to the active region (amino acids 17-23) responsible for actin regulation and cell motility. TB-500 has been studied across wound healing, cardiac repair, corneal injury, and hair growth contexts.[1][2]

What is thymosin beta-4?

Thymosin beta-4 is a 43-amino-acid protein found abundantly in most mammalian cells. It plays a central role in actin polymerisation, cell migration, and tissue repair. TB-500 is a synthetic version of its active region. The full protein has been studied in cardiac repair, wound healing, corneal injury, and neuroprotection research.[1][3][4]

What are TB-500 benefits?

Research-documented benefits include accelerated wound closure in animal models, improved cardiac function after ischaemic injury (including first human data in STEMI patients), corneal wound healing, hair follicle activation in mice, and anti-inflammatory activity. Human clinical data beyond cardiology remains limited.[2][3][4]

What are TB-500 side effects?

Commonly discussed side effects include headache, nausea, injection site reactions, and transient fatigue. The 2025 human cardiac study reported good tolerability. Broader human safety profiling at various concentrations remains limited. Person-to-person variability is substantial.[2][4]

TB-500 dose and TB-500 dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Dose and dosage intent is valid, but this profile focuses on mechanism context, evidence quality, and risk-aware interpretation. Refer to primary research literature for protocol parameters.

Does TB-500 help with hair growth?

Thymosin beta-4 has consistent animal evidence for hair growth via stem cell activation and migration. Philp et al. (2004) demonstrated hair growth by activation of follicle stem cells, and Gao et al. (2015) confirmed the effect in mouse models. However, no human hair growth trials exist for TB-500 or thymosin beta-4. The evidence is biologically plausible but clinically unconfirmed.[9][10]

TB-500 vs BPC-157: what is the useful comparison?

Both are studied in tissue-repair contexts but via distinct mechanisms. TB-500 operates via actin regulation and cell migration. BPC-157 works through angiogenesis and growth factor pathways with a broader gastric-protective profile. Neither has extensive human clinical data, though TB-500 now has the first cardiac human evidence. See BPC-157 vs TB-500 for a detailed breakdown.[2]

Is TB-500 backed by strong human evidence?

Human evidence is emerging. The 2025 Zhang et al. study in Cardiovascular Research provides the first controlled human cardiac data for thymosin beta-4. Other applications (wound healing, corneal repair, hair growth) remain at preclinical stage. The animal evidence base is extensive but translation to human outcomes outside cardiology is unconfirmed.[4]

TB-500 results: what does that usually mean in practice?

Usually trend-level recovery outcomes: improved movement tolerance, fewer interrupted training sessions, and steadier continuity over weeks rather than instant dramatic change. Confidence is highest when the same pattern repeats under stable conditions over multi-week windows.

Is TB-500 safe?

TB-500 was well tolerated in the 2025 human cardiac study. Beyond that, human safety data is limited. Animal studies across multiple tissue types have not raised significant safety concerns. As with all research peptides, the absence of comprehensive human safety trials means caution is appropriate.[2][4]

References

1. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037013.
2. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.
3. Philp D. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. PMID: 20536453.
4. Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction. Cardiovasc Res. 2025;121(4):cvaf024. PMID: 41229390.
5. Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. PMID: 11950239.
6. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99-104. PMID: 30063853.
7. Smart N, et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardial progenitors. Ann N Y Acad Sci. 2007;1112:171-188. PMID: 17495252.
8. Maar K, et al. Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals. Int J Mol Sci. 2025;26(8):3476. PMID: 40362372.
9. Gao X, et al. Thymosin Beta-4 Induces Mouse Hair Growth. PLoS One. 2015;10(6):e0130040. PMID: 26083021.
10. Philp D, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385-387. PMID: 14657002.
11. Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Glob Res Rev. 2026;10(1):e24.00304. PMID: 41490200.
12. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:1-9. PMID: 23084823.
13. Ou H, et al. Thymosin beta-4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo. Int Immunopharmacol. 2026;148:114091. PMID: 41443105.